NDAORALTABLET
Approved
Apr 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
17
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (17)
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Started Oct 2026
28 enrolled
Berger DiseaseBergers DiseaseIgA Nephropathy+3 more
IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection
Started May 2026
80 enrolled
IgA Nephropathy
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
Started Jul 2023
54 enrolled
IgA NephropathyImmunoglobulin A Nephropathy
Atrasentan in Patients With Proteinuric Glomerular Diseases
Started Mar 2021
103 enrolled
IgA NephropathyFocal Segmental GlomerulosclerosisAlport Syndrome+3 more
Atrasentan Spermatogenesis and Testicular Function
Started Apr 2015
20 enrolled
NephropathyDiabetes
Worked on VANRAFIA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.